Alkermes Plc
NASDAQ:ALKS

Watchlist Manager
Alkermes Plc Logo
Alkermes Plc
NASDAQ:ALKS
Watchlist
Price: 29.09 USD -0.82% Market Closed
Market Cap: 4.8B USD

EV/EBITDA
Enterprise Value to EBITDA

9.3
Current
8.7
Median
4.6
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
9.3
=
Enterprise Value
3.9B USD
/
EBITDA
420.4m USD
EBITDA Growth EV/EBITDA to Growth
IE
Alkermes Plc
NASDAQ:ALKS
Average EV/EBITDA: 14.3
9.3
-9%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -198 911.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.2
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
6%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.3
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -568 N/A N/A
AU
CSL Ltd
ASX:CSL
16.9
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.9
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.1 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -670.3 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
11.8
2-Years Forward
EV/EBITDA
10.3
3-Years Forward
EV/EBITDA
11.7